BIOVENTIX PLC revenue for the last year amounted to 14.91 M EUR, the most of which — 14.91 M EUR — came from its highest performing source at the moment, Sheep Monoclonal Antibodies, the year earlier bringing 13.61 M EUR. The greatest contribution to the revenue figure was made by Rest of the World — last year it brought BIOVENTIX PLC 11.93 M EUR, and the year before that — 11.15 M EUR.